Search
Haemagglutinin-strain A(H1N1)
go.drugbank.com/drugs/DB15476ApprovedInvestigationalMixtures: Influvac Suspension for InjectionPropiverine
go.drugbank.com/drugs/DB12278ApprovedPropiverine hydrochloride is a bladder detrusor muscle relaxant drug with dual antimuscarinic and calcium-modulating properties for the treatment of OAB [L2317].
Categories: Drugs for Urinary Frequency and IncontinenceDPI-221
go.drugbank.com/drugs/DB06121ExperimentalDPI-221 is an investigational drug and a selective agonist for the δ-opioid receptor.
Bexotegrast
go.drugbank.com/drugs/DB16515InvestigationalPhase 2a studies are currently evaluating PLN-74809 safety and efficacy for participants with IPF (NCT04396756)across 10 participating countries[L31703], and for participants with PSC (NCT04480840). … In addition, the compound is also currently in Phase 2a trials (NCT04565249) for the treatment of COVID-19 related acute respiratory distress syndrome[L31713].
Categories: Experimental Unapproved Treatments for COVID-19Berdazimer
go.drugbank.com/drugs/DB18712Approved[A262965] On Jan 05, 2024, the FDA approved berdazimer under the brand name ZELSUVMI for the treatment of adult and pediatric molluscum contagiosum, and it is the first drug to be approved for this … [A262960] Berdazimer was previously investigated as a potential treatment for molluscum contagiosum, a viral cutaneous infection mainly affecting children, sexually active adults, and immunocompromised
Hydroxypropyl cellulose
go.drugbank.com/drugs/DB00840ApprovedLacrisertis a formulation of hydroxypropyl cellulose that is used for artificial tears. … syndromes characterized by insufficient tear production (keratoconjunctivitis sicca), recurrent corneal erosions, decreased corneal sensitivity, exposure and neuroparalytic keratitis, and as a lubricant for
Crotamiton
go.drugbank.com/drugs/DB00265ApprovedCrotamiton is a scabicidal and antipruritic agent available as a cream or lotion for topical use only. It is a colorless to slightly yellowish oil, having a faint amine-like odor.
Caroxazone
go.drugbank.com/drugs/DB09254ApprovedWithdrawnHowever, it presents a five-fold preference for the MAO-B subtype.
Taletrectinib
go.drugbank.com/drugs/DB18711ApprovedInvestigational[A274158] As part of the second-generation of ROS1 inhibitors, taletrectinib is significantly more potent against ROS1 resistance mutations - for example, the IC50 for taletrectinib against ROS1 exhibiting … [A274118] Taletrectinib was approved by the US FDA in June 2025 for use in patients with advanced ROS1-positive NSCLC.[L53308,L53523]
Cyclopentolate
go.drugbank.com/drugs/DB00979ApprovedA parasympatholytic anticholinergic used solely to obtain mydriasis or cycloplegia.